Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Current Assets (2021 - 2025)

Kiniksa Pharmaceuticals International's Current Assets history spans 5 years, with the latest figure at $527.2 million for Q4 2025.

  • For Q4 2025, Current Assets rose 58.88% year-over-year to $527.2 million; the TTM value through Dec 2025 reached $527.2 million, up 58.88%, while the annual FY2025 figure was $527.2 million, 58.88% up from the prior year.
  • Current Assets reached $527.2 million in Q4 2025 per KNSA's latest filing, up from $475.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $527.2 million in Q4 2025 to a low of $179.9 million in Q2 2022.
  • Average Current Assets over 5 years is $290.1 million, with a median of $263.3 million recorded in 2023.
  • Peak YoY movement for Current Assets: fell 27.87% in 2022, then skyrocketed 58.88% in 2025.
  • A 5-year view of Current Assets shows it stood at $196.4 million in 2021, then increased by 23.73% to $243.1 million in 2022, then rose by 13.67% to $276.3 million in 2023, then grew by 20.09% to $331.8 million in 2024, then surged by 58.88% to $527.2 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Current Assets are $527.2 million (Q4 2025), $475.5 million (Q3 2025), and $420.3 million (Q2 2025).